In ASCVD, moderate-intensity statin + ezetimibe was noninferior to high-intensity statin alone at 3 y.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 36315955.
- Also identified by DOI 10.7326/J22-0085.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Kim BK, Hong SJ, Lee YJ, et al. <b>Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial.</b> Lancet. 202;400:380-90. 35863366.
Medical subject headings
- Atherosclerosis
- Ezetimibe
- Hydroxymethylglutaryl-CoA Reductase Inhibitors